A股異動 | 融鈺集團(002622.SZ)漲停 擬購買德倫醫療67%股權 快速切入醫療健康行業
格隆匯5月28日丨融鈺集團(002622.SZ)漲停,封單逾58萬手,現報5.47元,暫成交5591萬元,最新市值45.95億元。融鈺集團昨日晚間披露重大資產重組方案,公司擬以支付現金方式,向共青城德倫、歡樂基金購買德倫醫療52%、15%即合計67%的股權,目前交易價尚未最終確定。此次交易的業績承諾方共青城德倫,擬使用部分交易價款增持公司股票,成為公司股東。德倫醫療是一家口腔醫療服務的企業。目前,公司主要業績來源於電氣開關的銷售和軟件開發收入,通過此次交易,公司將快速切入醫療健康行業。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.